Literature DB >> 6324188

Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

E M Nelson, K M Tewey, L F Liu.   

Abstract

The intercalative acridine derivative 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), but not its isomer o-AMSA, is a potent antitumor drug that in mammalian cells stimulates the formation of DNA strand breaks that are characterized by tightly bound proteins. Using purified mammalian DNA topoisomerases, we have analyzed the effects of these antitumor drugs on topoisomerase-DNA interactions. The antitumor drug m-AMSA dramatically stimulates the formation of a topoisomerase II-DNA complex that is detected on protein-denaturant treatment: both single- and double-stranded DNA breaks are produced and a topoisomerase II subunit is linked covalently to each 5' end of the broken DNA strands. The noncytotoxic isomer, o-AMSA, which does not induce significant amounts of DNA breaks in cultured cells, exhibits a correspondingly smaller effect in stimulating formation of the complex in vitro. The agreement between in vitro and in vivo studies suggests that mammalian DNA topoisomerase II may be the primary target of m-AMSA and that the drug-induced complex formation between topoisomerase II and DNA may be the cause of cytotoxicity and other effects such as DNA sequence rearrangements and sister-chromatid exchange.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324188      PMCID: PMC344833          DOI: 10.1073/pnas.81.5.1361

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents.

Authors:  J W Lown; S K Sim; K C Majumdar; R Y Chang
Journal:  Biochem Biophys Res Commun       Date:  1977-06-06       Impact factor: 3.575

2.  Induction of limited DNA damage by the antitumor agent Cain's acridine.

Authors:  N B Furlong; J Sato; T Brown; F Chavez; R B Hurlbert
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

3.  On the mechanism of action of 4'-[(9-acridinyl)-amino] methanesulphon-m-anisidide.

Authors:  R K Ralph
Journal:  Eur J Cancer       Date:  1980-05       Impact factor: 9.162

4.  Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break.

Authors:  L F Liu; C C Liu; B M Alberts
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

5.  Ellipticine and derivatives induce breakage of L1210 cells DNA in vitro.

Authors:  C Paoletti; C Lesca; S Cros; C Malvy; C Auclair
Journal:  Biochem Pharmacol       Date:  1979       Impact factor: 5.858

Review 6.  DNA gyrase and the supercoiling of DNA.

Authors:  N R Cozzarelli
Journal:  Science       Date:  1980-02-29       Impact factor: 47.728

7.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

Authors:  B F Cain; G J Atwell
Journal:  Eur J Cancer       Date:  1974-08       Impact factor: 9.162

8.  Cell-cycle-specific chromosome damage following treatment of cultured Chinese hamster cells with 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide-HCl.

Authors:  L L Deaven; M S Oka; R A Tobey
Journal:  J Natl Cancer Inst       Date:  1978-05       Impact factor: 13.506

9.  Qualitative and quantitative aspects of intercalator-induced DNA strand breaks.

Authors:  W E Ross; D Glaubiger; K W Kohn
Journal:  Biochim Biophys Acta       Date:  1979-03-28

10.  Protein-associated DNA breaks in cells treated with adriamycin or ellipticine.

Authors:  W E Ross; D L Glaubiger; K W Kohn
Journal:  Biochim Biophys Acta       Date:  1978-06-22
View more
  113 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26.

Authors:  M P Lee; T Hsieh
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

4.  Purification and properties of DNA topoisomerase I from broccoli.

Authors:  J J Kieber; M F Lopez; A F Tissier; E Signer
Journal:  Plant Mol Biol       Date:  1992-03       Impact factor: 4.076

5.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

6.  Etoposide-induced DNA cleavage in human leukemia cells.

Authors:  C M Edwards; B S Glisson; C K King; S Smallwood-Kentro; W E Ross
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators.

Authors:  Y Pommier; J M Covey; D Kerrigan; J Markovits; R Pham
Journal:  Nucleic Acids Res       Date:  1987-08-25       Impact factor: 16.971

8.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 9.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  The effects of inhibitors of topoisomerase II and quinacrine on ultraviolet-light-induced DNA incision in normal and xeroderma pigmentosum fibroblasts.

Authors:  H W Thielmann; O Popanda; L Edler
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.